NCT06666803Recruiting
Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)
Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
Pancreatic ductal adenocarcinoma (PDAC) has the poorest prognosis of all digestive cancers due to lack of early diagnosis and limited response to treatment. Patient-derived organoid technology has become a mainstay of precision oncology, enabling personalised functional characterisation of tumours (e.g. treatment evaluation and drug screening). Initial research carried out as part of the Cancer Profile project has produced the first organoids from resected PDAC parts. Only 15-20% of patients can benefit from surgical resection, which remains the only curative treatment. In contrast, most patients with PDAC undergo diagnostic fine-needle biopsies (FNB) using an echo-endoscopic procedure (EUS). The next step is therefore the reliable generation of organoids from limited quantities of biopsy material obtained by 'EUS-FNB'. The aim of the study presented here is to validate these organoids on the basis of the following characteristics: (i) morphological and proliferative characteristics, (ii) recapitulation of the genetic characteristics of the original tumour, (iii) expression of tumour markers.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 23 Oct 2024
- Start date
- 27 Jan 2025
- Primary completion date
- Jan 2027
- Lead sponsor
- IHU Strasbourg
- Diseases
- Pancreatic cancer
- NCT number
- NCT06666803
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 27 Jan 2025 to the primary completion date, Jan 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient with acute pancreatitis within 4 weeks prior to EUS
Other
- Patient not programmed for endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB).
- Patient undergoing echo-endoscopy and presenting a high risk that may prevent EUS-FNB.
- Patient with degenerated Intraductal papillary mucinous neoplasm (IPMN)
- Pregnant or breast-feeding patient
- Patient under court protection.
- Patient under guardianship or curatorship.
- Patient in a situation of social vulnerability.
- Patient under legal protection or unable to express his/her opposition.
Who the study is looking for
- Adult patient over 18 years of age.
- Patient undergoing echo-endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB).
- Suspicion of pancreatic lesion
- Patient able to receive and understand information relating to the research protocol and to give consent.
- Patient affiliated to the French social security system.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of hepato-gastroenterology Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
| Centre d'Endoscopie Digestive Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.